Wayne Rothbaum

2.3k total citations
13 papers, 109 citations indexed

About

Wayne Rothbaum is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Wayne Rothbaum has authored 13 papers receiving a total of 109 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 7 papers in Hematology and 4 papers in Oncology. Recurrent topics in Wayne Rothbaum's work include Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Wayne Rothbaum is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Wayne Rothbaum collaborates with scholars based in United States, United Kingdom and France. Wayne Rothbaum's co-authors include Raquel Izumi, Jesse McGreivy, Ahmed Hamdy, John C. Byrd, Bart van Lith, Bonnie K. Harrington, Christopher C. Coss, Amy J. Johnson, Xiaoli Zhang and Allard Kaptein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Wayne Rothbaum

13 papers receiving 108 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wayne Rothbaum United States 6 64 43 37 32 28 13 109
Ivelise Rijo United States 5 38 0.6× 62 1.4× 45 1.2× 22 0.7× 32 1.1× 7 126
Stuart J. Blakemore United Kingdom 7 53 0.8× 28 0.7× 25 0.7× 25 0.8× 97 3.5× 9 155
Lesley Ann Sutton Sweden 5 57 0.9× 43 1.0× 27 0.7× 31 1.0× 33 1.2× 8 113
Sven Turkalj United Kingdom 5 40 0.6× 31 0.7× 31 0.8× 34 1.1× 47 1.7× 9 114
María Abáigar Spain 7 44 0.7× 19 0.4× 25 0.7× 90 2.8× 82 2.9× 16 150
Olga Stehlíková Czechia 7 56 0.9× 40 0.9× 22 0.6× 42 1.3× 51 1.8× 14 146
Hong L. Tiv United States 5 22 0.3× 13 0.3× 40 1.1× 50 1.6× 68 2.4× 7 130
Alejandro Medina Spain 6 32 0.5× 40 0.9× 32 0.9× 40 1.3× 45 1.6× 15 105
Jennifer A. Arzt United States 4 65 1.0× 58 1.3× 52 1.4× 15 0.5× 64 2.3× 5 151
Stefan Köhrer Austria 4 41 0.6× 54 1.3× 42 1.1× 32 1.0× 69 2.5× 11 153

Countries citing papers authored by Wayne Rothbaum

Since Specialization
Citations

This map shows the geographic impact of Wayne Rothbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wayne Rothbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wayne Rothbaum more than expected).

Fields of papers citing papers by Wayne Rothbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wayne Rothbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wayne Rothbaum. The network helps show where Wayne Rothbaum may publish in the future.

Co-authorship network of co-authors of Wayne Rothbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Wayne Rothbaum. A scholar is included among the top collaborators of Wayne Rothbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wayne Rothbaum. Wayne Rothbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations
2.
3.
Popov, Viola Maria, Sanjay Mohan, Zübeyde Nur Özkurt, et al.. (2024). Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 1000–1000. 4 indexed citations
4.
Nimmagadda, Subbaiah Chary, Todd Covey, Cecile M. Krejsa, et al.. (2023). Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 2782–2782. 1 indexed citations
5.
6.
7.
Wong, Michael K., Ciara M. Kelly, Melissa Burgess, et al.. (2020). KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy.. Journal of Clinical Oncology. 38(15_suppl). 10072–10072. 8 indexed citations
8.
9.
10.
Harrington, Bonnie K., Heather L. Gardner, Raquel Izumi, et al.. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE. 11(7). e0159607–e0159607. 43 indexed citations
11.
Overman, Michael J., Charles D. Lopez, Al B. Benson, et al.. (2016). A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 34(15_suppl). 4130–4130. 15 indexed citations
12.
Byrd, John C., Jeffrey A. Jones, Richard R. Furman, et al.. (2016). Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 34(15_suppl). 7521–7521. 14 indexed citations
13.
Byrd, John C., William G. Wierda, Jeffrey A. Jones, et al.. (2015). The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. Blood. 126(23). 831–831. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivelise Rijo Breakdown of academic impact, for papers by Stuart J. Blakemore Breakdown of academic impact, for papers by Lesley Ann Sutton Breakdown of academic impact, for papers by Sven Turkalj Breakdown of academic impact, for papers by María Abáigar Breakdown of academic impact, for papers by Olga Stehlíková Breakdown of academic impact, for papers by Hong L. Tiv Breakdown of academic impact, for papers by Alejandro Medina Breakdown of academic impact, for papers by Jennifer A. Arzt Breakdown of academic impact, for papers by Stefan Köhrer
Rankless by CCL
2026